12:00 AM
May 28, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Cell culture based pandemic influenza vaccine: Phase II started

Vivalis S.A. (Euronext:VLS, Nantes, France) said Kaketsuken began in April a Japanese Phase II trial to evaluate a cell culture-based pandemic flu vaccine. In...

Read the full 106 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >